{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:13:09Z","timestamp":1747195989594,"version":"3.40.5"},"reference-count":13,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Tibet Natural Science Foundation","award":["XZ2019ZR-ZY15(Z)"],"award-info":[{"award-number":["XZ2019ZR-ZY15(Z)"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"\nBackground<\/jats:title>\nA recent cluster of pneumonia cases in Wuhan, China, has been caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We propose the protocol described below to perform an individual-patient data (IPD) network meta-analysis (NMA) in order to evaluate the efficacies of different antiviral drugs to treat patients with coronavirus disease 2019 (COVID-19).<\/jats:p>\n<\/jats:sec>\n\nMaterials and methods<\/jats:title>\nWe will search the Medline, EMBASE, Cochrane Library, SinoMed, CNKI and VIP databases from their inceptions through July 2020. There will be no restrictions on language, publication year, or publication type. Randomized clinical trials (RCTs) and prospective cohort studies with antiviral treatments for COVID-19 will be considered. Two reviewers will independently select studies and collect data. Risk-of-bias assessments will be completed using the Cochrane risk-of-bias scale. Primary outcome will be the COVID-19 recovery rate. We will combine aggregated data from IPD with the NMA in a single model, compare the effects of different antiviral drugs on patient-relevant efficacy, and rank the results to decide which is the most effective.<\/jats:p>\n<\/jats:sec>\n\nTrial registration<\/jats:title>\nPROSPERO registration number: CRD42020167038<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0241947","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T18:34:37Z","timestamp":1604946877000},"page":"e0241947","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative effectiveness and safety of antiviral agents for patients with COVID-19: Protocol for a systematic review and individual-patient data network meta-analysis"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8561-4188","authenticated-orcid":true,"given":"Yulong","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhizhong","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiqiu","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"pone.0241947.ref001","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster","author":"JF-W Chan","year":"2020","journal-title":"Lancet"},{"key":"pone.0241947.ref002","unstructured":"Organization WH. Coronavirus disease 2019 (COVID-19) situation report\u2013 102 [cited 2020 May 1]. Available from: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports\/."},{"key":"pone.0241947.ref003","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","author":"N Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0241947.ref004","unstructured":"China NHCoPsRo. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia, (Trial Version 7) [cited 2020 March 3]. Available from: http:\/\/www.nhc.gov.cn\/yzygj\/s7653p\/202003\/46c9294a7dfe4cef80dc7f5912eb1989.shtml."},{"issue":"19","key":"pone.0241947.ref005","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19","volume":"382","author":"B Cao","journal-title":"N Engl J Med"},{"issue":"21","key":"pone.0241947.ref006","article-title":"A Trial of Lopinavir-Ritonavir in Covid-19","volume":"382","author":"P Dalerba","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0241947.ref007","first-page":"10","article-title":"First Case of 2019 Novel Coronavirus in the United States","volume":"2020","author":"ML Holshue","journal-title":"The New England journal of medicine"},{"key":"pone.0241947.ref008","unstructured":"Health NIo. NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID-19 [cited 2020 April 29]. Available from: https:\/\/www.nih.gov\/news-events\/news-releases\/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19."},{"key":"pone.0241947.ref009","unstructured":"Gilead Sciences I. Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19 [cited 2020 April 29]. Available from: https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/4\/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19."},{"journal-title":"The Lancet","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","author":"Y Wang","key":"pone.0241947.ref010"},{"issue":"1","key":"pone.0241947.ref011","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","author":"B Rouse","year":"2017","journal-title":"Intern Emerg Med"},{"key":"pone.0241947.ref012","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"L Shamseer","year":"2015","journal-title":"BMJ"},{"issue":"1","key":"pone.0241947.ref013","doi-asserted-by":"crossref","first-page":"e010251","DOI":"10.1136\/bmjopen-2015-010251","article-title":"Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: protocol for a systematic review and individual patient data network meta-analysis","volume":"6","author":"AA Veroniki","year":"2016","journal-title":"BMJ Open"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0241947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T18:34:53Z","timestamp":1604946893000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0241947"}},"subtitle":[],"editor":[{"given":"Muhammad","family":"Adrish","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":13,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0241947","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2020,11,9]]}}}